Every 10-Q that Utah Medical Products Inc (UTMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow UTMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UTMD filings page.
Utah Medical Products, Inc. reported weaker results for the quarter and first half ended June 30, 2026, with 2Q 2026 net sales of $8,529 thousand, down 14.3% from 2Q 2025, and 1H 2026 sales of $17,252 thousand, down 12.3%. Net income declined 11.9% in 2Q to $2,686 thousand and 13.1% in 1H to $5,290 thousand, while diluted EPS fell to $0.84 for 2Q and $1.66 for 1H.
The declines were driven mainly by the loss of two formerly largest customers, which accounted for most of the year-over-year sales decrease, only partially offset by limited new biopharma OEM sales. Management now projects full-year 2026 revenue to decline 10–13% versus 2025, versus an earlier expectation of flat sales. Litigation expenses rose to $935 thousand in 1H 2026 and U.S. tariffs on Filshie devices reduced gross margin.
Despite lower volumes, profitability metrics remain strong: 2Q 2026 gross margin was 55.8% and operating margin 31.1%. The balance sheet is conservative, with $87,528 thousand in cash and investments, no debt, a current ratio of 48.6, and working capital of $98,569 thousand. The company continued returning capital via $1,976 thousand in dividends (37% of 1H net income) and $206 thousand of open-market share repurchases.
Utah Medical Products reported lower first-quarter 2026 results, with solid margins but declines in sales and earnings versus a strong prior year. Net sales were $8,722k, down 10.2% from $9,710k, mainly due to the loss of a major China blood pressure monitoring distributor and an OEM customer.
Net income was $2,604k versus $3,041k, a 14.4% decrease, and diluted EPS fell to $0.82 from $0.92, helped somewhat by share repurchases that reduced the share count. Despite lower profit, gross margin improved to 60.6% from 57.0% on a more favorable product mix and a standard cost adjustment.
The company generated $3,109k of operating cash flow (down from $4,464k), ended the quarter with $87,406k in cash and investments, no debt, and stockholders’ equity of $120,373k. Utah Medical Products repurchased 2,196 shares for $129k and paid $989k in dividends while maintaining a very high current ratio and emphasizing continued buybacks and dividends as capital allocation priorities.
Utah Medical Products (UTMD) filed its Q3 2025 report showing sales of $9.812M and diluted EPS of $0.82. Gross margin was 57.1% and operating margin 26.6%, both lower year over year as operating income fell 21.9%.
Management cited two outside‑U.S. distributor cancellations/delays that reduced shipments by $976 and revenues by $581, and recorded a $395 bad‑debt reserve tied to a China distributor fee. Non‑operating income eased with lower cash yields. By category, Q3 sales were Gynecology/Electrosurgery/Urology $4.954M (down), Neonatal $2.176M (up), Blood Pressure Monitoring $1.643M (down), and Labor & Delivery $1.039M (flat).
Year to date, sales were $29.475M and EPS $2.68. Cash and investments were $84.267M, current liabilities $3.011M. The company repurchased 130,984 shares for $7.361M and paid $3.006M in dividends. Management now expects 2025 revenue to be 6–7% lower than 2024 and EPS of $3.40–$3.50.
Utah Medical Products (UTMD) reported Q2 2025 net sales of $9,953 thousand, down 4.3% from $10,400 in Q2 2024, and first-half sales of $19,663 thousand, down 9.6% year-over-year. Gross profit fell to $5,595 thousand (56.2% margin) from $6,253 thousand (60.1%), driven by lower volumes, an unfavorable product mix in Ireland and reduced orders from former large OEM customer PendoTECH. Net income was $3,048 thousand in Q2 and $6,089 thousand for 1H 2025; diluted EPS were $0.94 and $1.86, respectively.
The company remains well capitalized with $82.2 million in cash and investments, no debt, ongoing dividends and opportunistic share repurchases (119,255 shares repurchased in 1H 2025 for $6.7 million). Management expects full-year PendoTECH sales to be about $2.0 million lower than 2024, is tracking adjusted EBITDA near targets, and highlights potential OUS tariff and distributor-timing risks that could affect 2H results.